See more : Leef Brands Inc. (ICAN.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Immuneering Corporation (IMRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Immuneering Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- MODERN ENGINEERING AND PROJECT (MEAPL.BO) Income Statement Analysis – Financial Results
- Arrow Exploration Corp. (AXL.L) Income Statement Analysis – Financial Results
- Altitude Group plc (ALT.L) Income Statement Analysis – Financial Results
- China City Infrastructure Group Limited (2349.HK) Income Statement Analysis – Financial Results
- Strait Innovation Internet Co., Ltd. (300300.SZ) Income Statement Analysis – Financial Results
Immuneering Corporation (IMRX)
About Immuneering Corporation
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 316.95K | 2.08M | 2.31M | 1.92M |
| Cost of Revenue | 764.14K | 158.12K | 1.15M | 1.28M | 1.22M |
| Gross Profit | -764.14K | 158.83K | 926.89K | 1.03M | 696.74K |
| Gross Profit Ratio | 0.00% | 50.11% | 44.56% | 44.61% | 36.29% |
| Research & Development | 41.40M | 36.27M | 26.54M | 15.00M | 4.28M |
| General & Administrative | 16.76M | 15.61M | 8.27M | 3.11M | 2.71M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.76M | 15.61M | 8.27M | 3.11M | 2.71M |
| Other Expenses | 0.00 | 30.05K | -127.06K | 0.00 | 0.00 |
| Operating Expenses | 58.41M | 51.90M | 34.81M | 18.11M | 6.99M |
| Cost & Expenses | 58.41M | 52.06M | 35.97M | 19.39M | 8.21M |
| Interest Income | 3.61M | 1.01M | 169.90K | 42.66K | 57.66K |
| Interest Expense | 0.00 | 1.01M | 0.00 | 0.00 | 351.30K |
| Depreciation & Amortization | 352.08K | 796.79K | 159.07K | 79.31K | 18.08K |
| EBITDA | -58.06M | -51.47M | -33.68M | -17.00M | -7.34M |
| EBITDA Ratio | 0.00% | -16,316.29% | -1,629.17% | -733.74% | -382.35% |
| Operating Income | -58.41M | -51.74M | -33.89M | -17.08M | -6.29M |
| Operating Income Ratio | 0.00% | -16,325.77% | -1,629.17% | -739.01% | -327.71% |
| Total Other Income/Expenses | 4.94M | 1.23M | 42.84K | 42.66K | -1.42M |
| Income Before Tax | -53.47M | -50.51M | -33.84M | -17.04M | -7.71M |
| Income Before Tax Ratio | 0.00% | -15,937.29% | -1,627.11% | -737.17% | -401.59% |
| Income Tax Expense | 0.00 | -1.23M | -307.49K | -84.34K | 351.30K |
| Net Income | -53.47M | -49.28M | -33.54M | -17.04M | -8.06M |
| Net Income Ratio | 0.00% | -15,548.66% | -1,612.33% | -737.17% | -419.89% |
| EPS | -1.88 | -1.87 | -1.27 | -0.67 | -0.32 |
| EPS Diluted | -1.88 | -1.87 | -1.27 | -0.67 | -0.32 |
| Weighted Avg Shares Out | 28.42M | 26.39M | 26.32M | 25.51M | 25.51M |
| Weighted Avg Shares Out (Dil) | 28.42M | 26.39M | 26.32M | 25.51M | 25.51M |
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, announced today that it will be presenting preclinical data on its...
Immuneering to Participate in the Cowen 44th Annual Health Care Conference
CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the Cowen 44th Annual Health...
Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
- Topline data from the Phase 1 portion of Phase 1/2a trial of IMM-1-104 expected in March 2024 - - Dosing of first patient in the expanded Phase 2a portion of Phase 1/2a trial of IMM-1-104 expected in March 2024;...
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
– Fast Track designation has the potential to accelerate lead asset IMM-1-104's path to U.S. FDA submission for pancreatic ductal adenocarcinoma –
Immuneering Announces Participation in February Investor Conferences
CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in two February investor conferences to discuss...
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
- Dosing of first patient in the Phase 1/2a clinical trial expected in early 2024 - CAMBRIDGE, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop universal-RAS/RAF medicines for broad populations...
Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference
CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present...
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates
-Dose evaluation portion of IMM-1-104 Phase 1/2a trial approximately two-thirds enrolled; Immuneering's recommendation for a Phase 2 dose expected in early 2024 -
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
– Expanded benchmarking of IMM-1-104 as a single agent across more than 190 patient-aligned models in humanized 3D-tumor growth assays demonstrated high sensitivity in a wide range of MAPK-driven tumor types, including models of RAS and RAF mutant melanoma, pancreatic...
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that it will present preclinical...
Source: https://incomestatements.info
Category: Stock Reports